ZA9410090B - Methods for inhibiting weight gain or inducing weight loss - Google Patents

Methods for inhibiting weight gain or inducing weight loss

Info

Publication number
ZA9410090B
ZA9410090B ZA9410090A ZA9410090A ZA9410090B ZA 9410090 B ZA9410090 B ZA 9410090B ZA 9410090 A ZA9410090 A ZA 9410090A ZA 9410090 A ZA9410090 A ZA 9410090A ZA 9410090 B ZA9410090 B ZA 9410090B
Authority
ZA
South Africa
Prior art keywords
methods
inhibiting
inducing
weight loss
weight
Prior art date
Application number
ZA9410090A
Other languages
English (en)
Inventor
Henry Uhlman Bryant
Jeffrey Alan Dodge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA9410090B publication Critical patent/ZA9410090B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA9410090A 1993-12-21 1994-12-19 Methods for inhibiting weight gain or inducing weight loss ZA9410090B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,291 US5578613A (en) 1993-12-21 1993-12-21 Methods for inhibiting weight gain or inducing weight loss

Publications (1)

Publication Number Publication Date
ZA9410090B true ZA9410090B (en) 1996-06-19

Family

ID=22623225

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9410090A ZA9410090B (en) 1993-12-21 1994-12-19 Methods for inhibiting weight gain or inducing weight loss

Country Status (16)

Country Link
US (2) US5578613A (ja)
EP (1) EP0659423A1 (ja)
JP (1) JPH07196492A (ja)
KR (1) KR950016741A (ja)
CN (1) CN1107707A (ja)
AU (1) AU8154094A (ja)
CA (1) CA2138455A1 (ja)
CZ (1) CZ322294A3 (ja)
HU (1) HUT71342A (ja)
IL (1) IL112044A (ja)
NO (1) NO944923L (ja)
NZ (1) NZ270182A (ja)
PH (1) PH31266A (ja)
RU (1) RU94044357A (ja)
TW (1) TW272126B (ja)
ZA (1) ZA9410090B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
KR20010052891A (ko) 1998-06-16 2001-06-25 피터 지. 스트링거 아세틸콜린 수치를 상승시키는 방법
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US20060088860A1 (en) * 2004-09-13 2006-04-27 Lipomics Technologies, Inc. Metabolite markers for weight management
CA2588087A1 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
CA2707549A1 (en) 2007-12-03 2009-06-11 Itzik Harosh Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
WO2013102207A1 (en) * 2011-12-30 2013-07-04 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW303299B (ja) * 1993-07-22 1997-04-21 Lilly Co Eli

Also Published As

Publication number Publication date
NO944923L (no) 1995-06-22
AU8154094A (en) 1995-06-29
RU94044357A (ru) 1996-10-20
IL112044A (en) 1999-01-26
US5578613A (en) 1996-11-26
HUT71342A (en) 1995-11-28
IL112044A0 (en) 1995-03-15
HU9403673D0 (en) 1995-02-28
CA2138455A1 (en) 1995-06-22
US5578614A (en) 1996-11-26
EP0659423A1 (en) 1995-06-28
CZ322294A3 (en) 1995-09-13
NO944923D0 (no) 1994-12-19
CN1107707A (zh) 1995-09-06
JPH07196492A (ja) 1995-08-01
NZ270182A (en) 1996-08-27
PH31266A (en) 1998-06-18
KR950016741A (ko) 1995-07-20
TW272126B (ja) 1996-03-11

Similar Documents

Publication Publication Date Title
GB9419218D0 (en) Methods
ZA947933B (en) Methods for inhibiting bone loss
HU9403673D0 (en) Methods for inhibiting weight gain or inducing weight loss
GB2272121B (en) Amplifiers
EP0605164A3 (en) Checkweigher.
PL305453A1 (en) Fungicide
IL110540A0 (en) High molecular weight desulphatohirudin
GB2284336B (en) Fishing weight apparatus
GB9315340D0 (en) Methods
GB9316706D0 (en) Divers weight
GB9308780D0 (en) Methods
GB2278313B (en) Protective structure
GB9315271D0 (en) Methods
HU910047D0 (en) Process for the protection of holes or heading-walls
GB9302822D0 (en) Protective means
GB9310041D0 (en) Weight training aid
GB9208395D0 (en) Biocides
GB9318319D0 (en) Weight related alarm
AU6187594A (en) Correct weight
GB9320760D0 (en) Protective method
GB9320980D0 (en) Protective bollows
GB9301212D0 (en) Putting practice aid
GB9304364D0 (en) Survival aid
GB9322922D0 (en) Improved methods of sublimation
HU9501250D0 (en) 20-cyano-pregnan-21-oate derivative